Student Scientific Circle of Oncology and Radiotherapy, Medical University of Gdansk, 80-210 Gdansk, Poland.
Division of Oncology, Department of Internal Medicine, Comprehensive Cancer Center Graz, Medical University of Graz, 8036 Graz, Austria.
Int J Mol Sci. 2023 Sep 14;24(18):14114. doi: 10.3390/ijms241814114.
Despite tremendous progress in cancer treatment in recent years, treatment resistance is still a major challenge for a great number of patients. One of the main causes is regulatory T lymphocytes (Tregs), which suppress excessive inflammatory responses via the secretion of immunosuppressive cytokines and upregulate the immune checkpoints. Their abundance causes an immunosuppressive reprogramming of the tumor environment, which is ideal for tumor growth and drug inefficiency. Hence, regiments that can regain tumor immunogenicity are a promising strategy to overcome Tregs-mediated drug resistance. However, to develop effective therapeutic regimens, it is essential to understand the molecular mechanisms of Treg-mediated resistance. In this article, we gathered a comprehensive summary of the current knowledge on molecular mechanisms and the role of Tregs in cancer treatment resistance, including cancer immunotherapy, targeted therapy, chemotherapy, and radiotherapy.
尽管近年来在癌症治疗方面取得了巨大进展，但治疗耐药仍然是许多患者面临的主要挑战之一。其中一个主要原因是调节性 T 淋巴细胞（Tregs），它们通过分泌免疫抑制细胞因子来抑制过度的炎症反应，并上调免疫检查点。它们的丰度导致肿瘤微环境的免疫抑制重新编程，这有利于肿瘤生长和药物无效。因此，能够恢复肿瘤免疫原性的调节剂是克服 Tregs 介导的耐药性的一种有前途的策略。然而，要开发有效的治疗方案，了解 Treg 介导的耐药性的分子机制至关重要。在本文中，我们综合总结了目前关于 Tregs 在癌症治疗耐药性中的分子机制和作用的知识，包括癌症免疫疗法、靶向治疗、化疗和放疗。
Zotero 插件
